Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications

This analysis follows our recent study showing that Canadian public reimbursement delays have lengthened from regulatory approval to listing decisions by public drug plans and delayed public access to innovative medicines, mainly due to processes following the Common Drug Review (CDR) and the pan-Ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Salek, Sam M., Lussier Hoskyn, Sarah, Johns, Jeffrey, Allen, Nicola, Sehgal, Chander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387957/
https://www.ncbi.nlm.nih.gov/pubmed/30833899
http://dx.doi.org/10.3389/fphar.2018.01578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387957/
https://www.ncbi.nlm.nih.gov/pubmed/30833899
http://dx.doi.org/10.3389/fphar.2018.01578

Ejemplares similares